Treatment of relapsing-remitting multiple sclerosis patients with IFN-β1b: Results of a 6-year follow-up

Journal of Interferon and Cytokine Research

Volumn 26, Issue 2, 2006, Pages 96-100

  Bencsik, Krisztina ^a   Füvesi, Judit ^a   Fricska Nagy, Zsanett ^a   Rajda, Cecília ^a   Losonczi, Erika ^a   Török, Margit ^a   Vécsei, László ^a,b  

^a UNIVERSITY OF SZEGED   (Hungary)

^b UNIVERSITY OF SZEGED   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

GLATIRAMER; INTERFERON BETA SERINE; BETA INTERFERON; INTERFERON BETA-1B; RECOMBINANT PROTEIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DETERIORATION; DISEASE COURSE; DRUG EFFICACY; EXPANDED DISABILITY STATUS SCALE; FEMALE; FEVER; FLU LIKE SYNDROME; FOLLOW UP; HUMAN; MAINTENANCE THERAPY; MALE; MULTIPLE SCLEROSIS; MYALGIA; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; RELAPSE; REMISSION; LONGITUDINAL STUDY; PATHOLOGY; RECURRENT DISEASE; RETROSPECTIVE STUDY; TIME;

ADULT; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERFERON-BETA; LONGITUDINAL STUDIES; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RECOMBINANT PROTEINS; RECURRENCE; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 33644840643     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.2006.26.96     Document Type: Article

References (19)

1. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996;46:907-911.
2. Lublin FD, Whitaker JN, Eidelman BH, Millet AE, Arnason BG, Burks JS. Management of patients receiving interferon-beta-1b for multiple sclerosis: report of a consensus conference. Neurology 1996;46:12-18.
3. The IFNB Multiple Sclerosis Study Group. Interferon-beta-1b is effective in relapsing-remitting multiple sclerosis. 1. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-661.
4. Paty DW, Li DKB, the UBC MS/MRI Study Group, IFNB Multiple Sclerosis Study Group. Interferon-beta-1b is effective in relapsing-remitting multiple sclerosis. 2. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:662-667.
5. The Quality Standards Subcommittee of the American Academy of Neurology. Practice advisory on selection of patients with multiple sclerosis for treatment with Betaferon. Neurology 1994;44:1537-1540.
6. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, Johnson KP, Sibley WA, Silberberg DH, Tourtellotte WW. New diagnostic criteria for multiple sclerosis. Guidelines for research protocols. Ann. Neurol. 1983;13:227-231.
7. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;43:655-661.
8. Jacobs LD, Cookfair DL, Rudick RA. Intramuscular interferon-beta-1a for disease progression in relapsing-remitting multiple sclerosis. Ann. Neurol. 1996;39:285-294.
9. PRISMS Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-1504.
10. Arbizu T, Álvarez-Cermeno JC, Decap G, Fernández O, Uria DF, García Merino A, Izquierdo G, Montalbán X. Interferon beta-1b treatment in patients with relapsing-remitting multiple sclerosis under a standardized protocol in Spain. Acta Neurol. Scand. 2000;102:209-217.
11. Carrá A, Onaha P, Sinay V, Alvarez F, Luetic G, Bettinelli R, San Pedro E, Rodriguez L. A retrospective, observational study comparing the four available immunomodulatory treatments for relapsing-remitting multiple sclerosis. Eur. J. Neurol. 2003;10:671-676.
12. Onesti E, Bagnato F, Tomassini V, Denaro F, Frontoni M, Millefiorini E, Pozzilli C, Fieschi C. Interferon beta treatment of MS in the daily clinical setting: a 3-year post-marketing study. Neurol. Sci. 2003;24:340-345.
13. Milanese C, La Mantia L, Palumbo R, Martinelli V, Murialdo A, Zaffaroni M, Caputo D, Capra R, Bergamaschi R, the North Italy Multiple Sclerosis Group. A post-marketing study on interferon beta 1b and 1a treatment in relapsing-remitting multiple sclerosis: different response in drop-outs and treated patients. J. Neurol. Neurosurg. Psychiatry 2003;74:1689-1692.
14. Huber S, Spycher M, Lechner-Scott J, Bellaiche Y, Steck AJ, Kappos L. Multiple sclerose: Therapie mit rekombinantem Interferon beta-1b. Schweiz. Med. Wochenschr. 1996;126:1475-1481.
15. Khan OA, Tselis AC, Kamholz JA, Garbern JY, Lewis RA, Lisak RP. A prospective, open-label treatment trial to compare the effect Of IFN beta-1a (Avonex), IFN beta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis. Eur. J. Neurol. 2001;8:141-148.
16. Dubois BD, Keenan E, Porter BE, Kapoor R, Rudge P, Thompson AJ, Miller DH, Giovannoni G. Interferon beta in multiple sclerosis: experience in a British specialist multiple sclerosis centre. J. Neurol. Neurosurg. Psychiatry 2003;74:946-949.
17. Johnson KP, Brooks BR, Ford CC, Goodman A, Guarnaccia J, Lisak RP, Myers LW, Panitch HS, Pruitt A, Rose JW, Kachuck N, Wolinsky JS. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group. Mult. Scler. 2000;6:256-266.
18. Ebers G, Rice G, Traboulsee A, Kaskel P, Wolf C, Salazar-Grueso E. Long-term follow-up of interferon beta-1b pivotal trial RRMS patients: design issues of a 16-year follow-up study. Mult. Scler. 2004;10(Suppl 2):S247.
19. Ebers GC. Natural history of multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 2001;71(Suppl II):16-19.